EZH2 has been found to be highly expressed in many tumours, such as prostate cancer, breast cancer, colorectal cancer, hepatocellular carcinoma, lymphoma and head and neck squamous cell carcinoma (HNSCC)2. This evidence concerns the gene EZH2 and head and neck squamous cell carcinoma.